Muhammad Hashim Hayat

Muhammad Hashim Hayat

Auto-generated profile, based on publicly available information

Muhammad Hashim Hayat

Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
IZIoannis A. Ziogas
Ioannis A. Ziogas
AEAlexandros P. Evangeliou
Alexandros P. Evangeliou
DGDimitrios Giannis
Dimitrios Giannis
MHMuhammad H. Hayat
Muhammad H. Hayat
KMKonstantinos S. Mylonas
Konstantinos S. Mylonas
Georgios TsoulfasGeorgios Tsoulfas
Georgios Tsoulfas
Background Immune checkpoints inhibitors (ICIs) have emerged as a treatment option for several malignancies. Nivolumab, pembrolizumab, nivolumab plus ipilimumab, and atezolizumab plus bevacizumab have been approved for the management of advanced‐stage hepatocellular carcinoma (HCC). We aimed to systematically review the literature and summarize the characteristics and outcomes on HCC patients treated with ICIs. Methods A systematic literature search of PubMed, the Cochrane Library, and ClinicalTrials.gov was performed according to the PRISMA statement (end‐of‐search date: November 7th, 2020). Quality of evidence assessment was also performed. Results Sixty‐three articles including 2,402 patients were analyzed, 2,376 of whom received ICIs for unresectable HCC. Response to ICIs could be evaluated in 2,116 patients, and the overall objective response rate (ORR) and disease‐control rate (DCR) were 22.7% and 60.7%, respectively, and the mean overall survival (OS) was 15.8 months. The ORR, DCR and OS for nivolumab (n=846) were 19.7%, 51.1% and 18.7 months, respectively, and for pembrolizumab (n=435) were 20.7%, 64.6% and 13.3 months, respectively. The combination of atezolizumab/bevacizumab (n=460) demonstrated an ORR and DCR of 30% and 77%, respectively. The overall rate of treatment discontinuation due to adverse events was 14.9%. Fifteen patients received ICIs in the liver transplant (LT) setting (one pre‐LT for bridging, 14 for post‐LT recurrence); fatal graft rejection was reported in 40.0% (n=6/15) and mortality in 80.0% (n=12/15). Conclusion ICIs are safe and effective against unresectable HCC, but caution is warranted regarding their use in the LT setting due to the high graft rejection rate. Implications for Practice Our systematic review pooled the outcomes from studies reporting on the use of immune checkpoint inhibitors (ICIs) for the management of 2,402 patients with advanced‐stage hepatocellular carcinoma (HCC), 2,376 of whom had unresectable HCC. The objective response rate and disease‐control rate were 22.7% and 60.7%, respectively, and the mean overall survival was 15.8 months. The overall rate of treatment discontinuation due to adverse events was 14.9%. Fifteen patients received ICIs in the liver transplant (LT) setting (one pre‐LT for bridging, 14 for post‐LT recurrence). Six of the them experienced graft rejection (40.0%).

5 February 2021 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
MHMuhammad H. Hayat
Muhammad H. Hayat
MMMatthew H. Meyers
Matthew H. Meyers
IZIoannis A. Ziogas
Ioannis A. Ziogas
MEMajd A. El-Harasis
Majd A. El-Harasis
LHLawrence T. Heller
Lawrence T. Heller
KBKevin G. Buell
Kevin G. Buell

9 September 2020 in Cureus
Verified
Journal Article
Open access
PDF file
MHMuhammad Hashim Hayat
Muhammad Hashim Hayat
ZMZorays Moazzam
Zorays Moazzam
IZIoannis A. Ziogas
Ioannis A. Ziogas
AYAmman Yousaf
Amman Yousaf
MHMaham Hayat
Maham Hayat
Although mild elevations in liver enzymes are relatively common in thyrotoxicosis, acute liver failure (ALF) is an infrequent occurrence. Despite the emergence of liver transplantation as a viable treatment for ALF, survival rates continue to remain unsatisfactory, coupled with higher rates of postoperative complications and re-transplantation in this group. We present the disease course, management, and outcome of a patient with Graves’ disease who presented with ALF secondary to thyroid storm. Thyrotoxicosis should always be included in the differential diagnosis of ALF, as timely diagnosis and management are crucial in achieving survival.

1 November 2001 in European Journal of Anaesthesiology
Verified
Journal Article
Open access
PDF file
YYY. Yusim
Y. Yusim
HBH. Berkenstadt
H. Berkenstadt
IKI. Keidan
I. Keidan
MHM. Hayat
M. Hayat
APA. Perel
A. Perel
Unilateral malignant hyperinflation of the lungs during positive pressure mechanical ventilation was described during aggressive respiratory therapy of unilateral lung disease or in situations of significant difference in compliance between the two lungs. We report a case of malignant hyperinflation of the nondependent lung during chest surgery. The differential diagnosis and treatment with differential lung ventilation are described.


5 May 2021 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
MHMuhammad Hashim Hayat
Muhammad Hashim Hayat
AWAbdul Wahab
Abdul Wahab
RTRaseen Tariq
Raseen Tariq